UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 18, 2003
MANHATTAN PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware 0-27282 36-3898269
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
787 Seventh Avenue, 48th Floor
New York, New York 10019
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (212) 554-4525
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.
The Registrant's press release dated September 18, 2003, which is
attached to this Current Report on Form 8-K as Exhibit 99.1, is incorporated by
reference herein.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits
99.1 Company's press release dated September 18, 2003.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
MANHATTAN PHARMACEUTICALS, INC.
Date: September 23, 2003 By: /s/ Nicholas J. Rossettos
------------------------------------
Nicholas J. Rossettos
Chief Operating Officer and Chief
Financial Officer
2
EXHIBIT INDEX
99.1 Registrant's Press Release dated September 18, 2003.